Synergistic co‐targeting of prostate‐specific membrane antigen and androgen receptor in prostate cancer

JD Murga, SM Moorji, AQ Han, WW Magargal… - The …, 2015 - Wiley Online Library
BACKGROUND Antibody–drug conjugates (ADCs) are an emerging class of cancer
therapies that have demonstrated favorable activity both as single agents and as …
被引用次数：97 相关文章
[PDF] academia.edu

[PDF][PDF] Synergistic Co-Targeting of Prostate-Specif| c Membrane Antigen and Androgen Receptor in Prostate Cancer

JD Murga, SM Moorji, AQ Han, WW Magargal… - 2014 - academia.edu
BACKGROUND. Antibody-drug conjugates (ADCs) are an emerging class of cancer
therapies that have demonstrated favorable activity both as single agents and as …

Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer.

JD Murga, SM Moorji, AQ Han, WW Magargal… - The Prostate, 2014 - europepmc.org
Background Antibody-drug conjugates (ADCs) are an emerging class of cancer therapies
that have demonstrated favorable activity both as single agents and as components of …

[引用][C] Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer

JD Murga, SM Moorji, AQ Han, WW Magargal… - The Prostate, 2014 - cir.nii.ac.jp
Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in
prostate cancer | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ …

Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer

JD Murga, SM Moorji, AQ Han… - The …, 2015 - pubmed.ncbi.nlm.nih.gov
Background Antibody-drug conjugates (ADCs) are an emerging class of cancer therapies
that have demonstrated favorable activity both as single agents and as components of …